Daily Stock List
Adaptive Medias, Inc. (ADTM)
Equities Canada, Serious Traders, PennyStocks24, BUYINS.NET, Wall Street Resources, and Tip.us reported on Adaptive Medias, Inc. (ADTM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Adaptive Medias, Inc. is a foremost provider of mobile video delivery and monetization solutions for publishers, content producers and advertisers. The Irvine, California-based Company is a content syndication and monetization enterprise. It is a programmatic audience and content monetization provider for website owners, application (app) developers, and video publishers who want to more effectively optimize content via advertising.
Adaptive Medias provides a foundation for publishers and developers looking to engage brand advertisers by way of a multi-channel approach, which delivers integrated, engaging, and impactful ads across multiple devices. Adaptive Medias meets the needs of its publishers with an emphasis on maintaining user experience.
Concerning Networks, Adaptive Medias makes it easy for website publishers to connect with quality advertisers and get rewarded for driving conversions. The Company’s network partners’ work closely with its team to ensure publisher inventory is evaluated quickly and available for purchase.
Regarding Content Providers, Adaptive Medias provides content providers customized solutions. These solutions deliver premier monetization for their partners’ web sites.
Adaptive Medias has its Media Graph platform. Media Graph is its flagship product offering. It provides publishers, producers, and advertisers the ability to easily and effectively monetize digital video content across all screens and devices through one centralized solution.
Media Graph provides easy content ingestion and campaign setup; less reliance on multiple vendors; strong advertisement serving and cross-screen capabilities, and real-time campaign management. All platform users get access to an easy-to-navigate platform, an HTML5/Flash friendly custom video player designed for any device, express publishing capabilities, and encoding, video streaming and hosting services. Moreover, users get access to over one million pieces of premium video content available for syndication across all devices.
Last week, Adaptive Medias announced the release of its newest Digital Video Player (DVR) 4.0. With this new video player, the Company enables its clients to seamlessly deliver and effectively monetize digital content across all screens and devices. Player 4.0 is only a fraction of the size of its predecessor. Player 4.0 is faster and more lightweight in design.
Today, Adaptive Medias announced it received an acquisition proposal from private digital advertising technology company AdSupply, Inc., for $35 million, or $1.50 per share, in an all cash transaction. This offer represents a premium of almost 900 percent to Adaptive Medias’ closing stock price of $0.16 on January 27, 2016. AdSupply provides a private digital advertising marketplace for brands and agencies to purchase high engagement advertising across quality sites and apps - online and on mobile.
Adaptive Medias, Inc. (ADTM), closed Monday's trading session at $0.74, up 413.53%, on 882,480 volume with 547 trades. The average volume for the last 60 days is 47,550 and the stock's 52-week low/high is $0.07/$3.10.
Marina Biotech, Inc. (MRNA)
Marketbeat.com, SmarTrend Newsletters, SmallCapVoice, and OTC Markets Group reported earlier on Marina Biotech, Inc. (MRNA), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Marina Biotech, Inc. is a foremost nucleic acid-based drug discovery and development company concentrating on rare diseases. It is an oligonucleotide therapeutics enterprise with wide-ranging drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics. These include siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. Marina Biotech is based in Bothell, Washington.
The Company’s technologies were built via a roll-up strategy to discover and develop different kinds of nucleic acid therapeutics to modulate (up or down) a specific protein(s), which is either being produced too much or too little and consequently causing a particular disease.
Marina Biotech’s belief is that its technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. In addition, the Company believes it is the only one in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively.
Marina Biotech’s novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, MiNA Therapeutics, Monsanto, and Tekmira. At present, the Company’s pipeline includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy.
Marina Biotech is advancing CEQ508, for which it has received Food and Drug Administration (FDA) orphan drug designation, in a Phase 1 clinical program for patients with Familial Adenomatous Polyposis. It is expanding its rare disease focus to include myotonic dystrophy and Duchenne’s muscular dystrophy.
On September 28, 2015, Marina Biotech and Hongene Biotechnology Limited announced that they entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina Biotech's Conformationally Restricted Nucleotide (CRN) chemistry. In return, Marina Biotech will receive royalties from the sale of CRN-based reagents. The Agreement will also establish a ready supply of CRN amidites for Marina Biotech's therapeutic research and development efforts.
This past November, Marina Biotech reported that its SMARTICLES® licensee Mirna Therapeutics, Inc. (MIRN) announced the presentation of interim results from its continuing Phase I clinical trial of MRX34. Mirna's poster presentation was titled, "Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors". It was presented on November 8, 2015 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The poster reported interim Phase I clinical results for MRX34 from 75 patients with advanced solid tumors. MRX34 is Mirna's lead therapeutic candidate.
Marina Biotech, Inc. (MRNA), closed Monday's trading session at $0.20, up 23.46%, on 199,299 volume with 20 trades. The average volume for the last 60 days is 87,213 and the stock's 52-week low/high is $0.15/$0.695.
ChineseInvestors.com, Inc. (CIIX)
Stock Brain, HEROSTOCKS, PREPUMP STOCKS, Damn Good Penny Picks, Penny Stock Newsletter, Penny Picks, and PennyStocks24 reported earlier on ChineseInvestors.com, Inc. (CIIX), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
ChineseInvestors.com, Inc. provides Web-based real-time financial information in the Chinese language for the Chinese population in the U.S. and around the world. It offers its services through its Websites, and also through customer support personnel at its telemarketing and customer service centers. ChineseInvestors.com was established in 1999 and the Company lists on the OTC Bulletin Board.
ChineseInvestors.com provides real-time market commentary, analysis, and educational related services in the Chinese language character sets (traditional and simplified). The Company also provides support services to its various partners.
In addition, it provides consultative services to smaller private companies considering becoming a public company, and advertising and public relation related support services. Furthermore, the Company provides other services it may identify having the potential to create value or partnership opportunities with its existing services.
ChineseInvestors.com provides various subscription services, including information about U.S.-listed companies; real-time analysis and tracking of U.S. stock market quotations; trend analysis of the market and individual sectors; and access to a sample investment portfolio for educational simulation relative to individual stock research. It also provides real-time trading demonstrations of various trading techniques.
ChineseInvestors.com also provides educational demonstrations to its subscribers on how to evaluate different investments through fundamental and technical analysis; education materials; option investment and trading subscription services; dark horse subscription services that focus on U.S.-listed small-cap stocks; general content production services; and Website based advertising services. It additionally provides general corporate support services; and stocks and research tools.
This month, ChineseInvestors.com held a press conference at its San Gabriel, California office, and announced the opening of the ChineseInvestors.com Online Trading Education Institute. This is the first equity trading school for Chinese-language speakers in the United States. Chin Ho Liao, Vice Mayor of San Gabriel City, and Mary Su, Mayor of Walnut City, California attended the ceremony. Moreover, journalists from greater than 10 local Chinese media outlets came to cover the event.
The ChineseInvestors.com Online Trading Education Institute plans to open two sessions of courses - onsite and online this month. The instructors include the Company’s own staff: CEO Warren Wang, Chief Technical Analyst Jay Geng and Analyst Will Du. Instructors also include stock investment expert Howard Wang. He invented the Breakout Relative Strength Index (BRSI). Courses include a Beginner Class for the US Stock Millionaire Club, a CandleStick Chart Class, and more.
ChineseInvestors.com, Inc. (CIIX), closed Monday's trading session at $0.389, up 12.43%, on 117,467 volume with 38 trades. The average volume for the last 60 days is 4,872 and the stock's 52-week low/high is $0.25/$0.75.
Skinvisible, Inc. (SKVI)
Stock Guru, PennyStocks24, Xtremepicks, OurHotStockPicks, and Penny Stock Whispers reported previously on Skinvisible, Inc. (SKVI), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Incorporated in 1998, Skinvisible, Inc. (via its wholly-owned subsidiary Skinvisible Pharmaceuticals, Inc.) is a pharmaceutical research and development (R&D) company. It has developed and patented an inventive polymer delivery system, Invisicare®. Additionally, Skinvisible has formulated in excess of forty topical skin products that it out-licenses worldwide. The Company is headquartered in Las Vegas, Nevada and its shares trade on the OTC Markets Group’s OTCQB.
Skinvisible has many patents issued (technology and product patents). Its business model continues to be to out-license its patented prescription and Over-the-Counter (OTC) products featuring Invisicare to established manufacturers and marketers of brands globally. In addition, its business model continues to focus on maximizing profits from the products it has already out-licensed.
Furthermore, Skinvisible has created a commercial subsidiary, Kintari USA, Inc. This is to take its cosmeceutical and select OTC products with Invisicare® to market. Kintari USA is a wholly-owned subsidiary of Kintari International, Inc., a wholly-owned subsidiary of Skinvisible.
Kinatri USA is marketing a premium line of scientifically formulated skincare products powered by Skinvisible’s patented Invisicare® technology. Kintari USA products will sell through network marketing. The products will sell first in the United States, and subsequently in Canada this year.
Skinvisible states that the demand for its products is enhanced because of the granting of key U.S. and international patents, as well as the completed development of a number of innovative products. The Company has licensees internationally and two of the licensees are presently in the marketplace. These are Avon Products around the world and Women's Choice Pharmaceuticals in the U.S.
In late September 2015, Skinvisible Pharmaceuticals announced that it expanded its patent portfolio with a new patent granted by the United States Patent and Trademark Office (USPTO) entitled, "Acne Treatment Composition and Methods for Using." Skinvisible continues to build its global patent portfolio while looking for licensees for its prescription line of dermatology focused products.
The demand for a patent protected channel of dermatology products is growing fast as the worldwide medical dermatology market continues to develop and new molecules are not available. Companies are looking for products that are cost-effective and have patent protection to maximize exclusivity.
Skinvisible, Inc. (SKVI), closed Monday's trading session at $0.0249, up 24.50%, on 3,205,000 volume with 5 trades. The average volume for the last 60 days is 68,988 and the stock's 52-week low/high is $0.0151/$0.065.
Authentidate Holding Corp. (ADAT)
TopPennyStockMovers, PennyStocks24, Street Insider, and Tip.us reported earlier on Authentidate Holding Corp. (ADAT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Authentidate Holding Corp. is a provider of secure web-based revenue cycle management applications and telehealth products and services. These enable healthcare organizations to coordinate care for patients and enhance related administrative and clinical workflows. Authentidate’s healthcare customers and users include foremost homecare companies, health systems, physician groups, as well as governmental entities. These organizations use the Company’s products and services to manage care for patients outside of acute-care.
Authentidate’s products and services enable healthcare organizations to increase revenues, reduce costs and enhance patient care. This is through eliminating paper and manual work steps from clinical and administrative processes. Authentidate’s customers include top health systems such as the Department of Veterans Affairs, national home care companies such as Gentiva and Apria, numerous hospital systems and ACOs.
The Company’s telehealth solutions combine patient vital signs monitoring with a web application that streamlines patient care management. This is delivered as Software as a Service (SaaS). Customers only need an Internet connection and web browser to access Authentidate’s web-based applications, thus using previous investments in systems and technology.
Authentidate’s products include Inscrybe Hospital Discharge. This is a patient placement and discharge optimization tool. Its products also include InscrybeMD Electronic House Call and IVR. This is remote patient monitoring by way of a stand-alone device or Interactive Voice Response (IVR). In addition, its products include Inscrybe Healthcare. This is a referral management and document tracking solution.
Last week, Authentidate Holding announced that it plans to host a conference call on Tuesday, February 2, 2016, at 12:00 p.m. ET, to discuss its recently completed merger transaction. Privately-held AEON has merged with a wholly-owned subsidiary of Authentidate. This creates a company centered on delivering advanced solutions, which achieve technology best practices in medicine and raise the standard of healthcare. The call will be hosted by Mr. Richard Hersperger, the Company’s new CEO. Mr. Hersperger will take questions from investors.
AEON Clinical Laboratories is a growing comprehensive and efficient clinical laboratory utilizing state-of-the-art testing equipment. AEON has developed proprietary methodologies. These provide some of the fastest and most reliable urine and oral fluid (saliva) test results in the country. AEON provides health care professionals with four primary tests: Medical Toxicology, Pharmacogenomics, Cancer Genetic Testing, and Molecular Biology.
Authentidate Holding Corp. (ADAT), closed Monday's trading session at $3.17, down 4.23%, on 65,138 volume with 188 trades. The average volume for the last 60 days is 4,118 and the stock's 52-week low/high is $0.8101/$8.1908.
OurPet's Company (OPCO)
The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.89, up 4.09%, on 17,385 volume with 11 trades. The stock’s average daily volume over the past 60 days is 5,263, and its 52-week low/high is $0.45/$1.00.
OurPet's Company, exemplifying the company’s historical commitment to the development of products designed to enhance the bond between pets and humans, today announced a strategic partnership with Aplix IP Holdings Corp., a Japan-based software and solution provider. "We literally searched the world for the strategic partner who shares the same passion as we do and would closely work with us to bring these ideas to reality. We're fortunate to have found what we were looking for in Aplix of Japan, a world leader in Bluetooth and Wi-Fi design, development and manufacture of related components," says OurPet's CEO Dr. Steve Tsengas. "OurPet's and Aplix have invested extensive resources to develop new products fueled by smart technology and we look forward to collaborations that continue this development."
OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.
In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.
The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.
OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer
OurPet's Company Company Blog
OurPet's Company News:
OurPet's Commits to Further Innovation in Pet Products That Enhance Pet/Owner Relationship
Dean Tsengas Named Chief Operations Officer of OurPet's Company
OurPet's Company (OPCO) Named 'Company of the Month' in November Issue of The Bowser Report
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $2.35, up 11.90%, on 10,402 volume with 34 trades. The stock’s average daily volume over the past 60 days is 12,827, and its 52-week low/high is $1.25/$11.625.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.75, up 7.14%, on 6,145 volume with 7 trades. The stock’s average daily volume over the past 60 days is 18,528, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016
Oakridge Providing Batteries for Unmanned Maritime Vessels
Oakridge Sells Interest in Leclanche S.A., Releasing Funding for Corporate Growth
Lingo Media Corp. (LMDCF)
The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.58, up 4.28%, on 2,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 6,554, and its 52-week low/high is $0.0862/$0.6745.
Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.
The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.
Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.
Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer
Lingo Media Corp. Company Blog
Lingo Media Corp. News:
Lingo Media to Present at the World Outlook Financial Conference 2016 on January 29th & 30th
Lingo Media Corp. (LMDCF) (LM.V) Continues to Generate Strong Profits with Q3 Net Income of $631,730
Lingo Media to Present at the LD Micro Main Event
Star Mountain Resources, Inc. (SMRS)
The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $0.585, even for the day. The stock’s average daily volume over the past 60 days is 9,649, and its 52-week low/high is $0.405/$1.40.
Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.
Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.
The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.
Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer
Star Mountain Resources, Inc. Company Blog
Star Mountain Resources, Inc. News:
Star Mountain Resources, Inc. Closes Acquisition of Balmat Zinc Mine in New York State
Star Mountain Resources, Inc. to Acquire Balmat Zinc Mine in New York State
Star Mountain Resources Inc. (SMRS) Pursues Acquisition Opportunities in North American Mining Sector
Today's Top 3
The QualityStocks Public Company Sponsor News